All In Biotech

Drug Trial Radar · NCT04460885

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before

A 78-week Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Glargine 100 Units/mL, Both in Combination With Non-insulin Anti-diabetic Treatment, in Insulin naïve Subjects With Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 984 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

984

Actual

Start

Nov 25, 2020

Primary completion

May 29, 2022

Study completion Dec 1, 2022

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jul 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. Participants will either get insulin icodec that participants will have to inject once a week on the same day of the week or insulin glargine that participants will have to inject once a day at the same time every day. Which treatment participants get is decided by chance. The insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach. The study will last for about 1 ½ years. Participants will have 37 clinic visits and 26 phone calls with the study doctor. At 11 clinic visits participant will have blood samples taken. At 8 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Participants will be asked to wear a sensor that measures the blood sugar all the time in 5 periods of about one month during the study (about 5 months in total). Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Insulin icodecDrug

    Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 78 weeks.

  • Insulin glargineDrug

    Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 78 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycated Haemoglobin (HbA1c)Time frame: Baseline (week 0), Week 52

Locations

198 sites in 13 countries. Site status is shown where the registry gives one.

  • Uni of Alabama at Birmingham

    Birmingham, Alabama

  • Lakeview Clinical Research, LLC

    Guntersville, Alabama

  • Lynn Institute of the Ozarks

    Little Rock, Arkansas

  • Anaheim Clinical Trials

    Anaheim, California

  • Advanced Clinical Research/Rancho Paseo Medical Group

    Banning, California

  • American Clinical Trials

    Buena Park, California

  • San Fernando Valley Hlth Inst, LLC

    Canoga Park, California

  • Med Center Medical Clinic

    Carmichael, California

  • Headlands Research California, LLC

    Escondido, California

  • Valley Research

    Fresno, California

  • Scripps Whittier Diabetes Inst

    La Jolla, California

  • First Valley Medical Group

    Lancaster, California

  • Clinical Trials Research_Sacramento

    Lincoln, California

  • Torrance Clin Res Inst, Inc.

    Lomita, California

  • Providence Clinical Research

    North Hollywood, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California

  • NorCal Endocrinology and Internal Medicine_Roseville

    Roseville, California

  • Diabetes Research Center

    Tustin, California

  • Coastal Metabolic Research Center

    Ventura, California

  • Denver Endocrinology Diabetes and Thyroid Center

    Englewood, Colorado

  • Chase Medical Research LLC

    Waterbury, Connecticut

  • Revival Research

    Doral, Florida

  • East Coast Institute for Research, LLC

    Jacksonville, Florida

  • Jacksonville Ctr For Clin Res

    Jacksonville, Florida

  • University Of Miami

    Miami, Florida

  • Suncoast Clin Res Port Richey

    New Port Richey, Florida

  • Florida Inst For Clin Res

    Orlando, Florida

  • Palm Harbor Medical Associates

    Palm Harbor, Florida

  • Suncoast Clinical Research, Inc.

    Palm Harbor, Florida

  • Metabolic Research Institute Inc

    West Palm Beach, Florida

  • Clinical Research of Cent FL

    Winter Haven, Florida

  • Atlanta VA Medical Center

    Decatur, Georgia

  • Physicians Research Assoc. LLC

    Lawrenceville, Georgia

  • RNA America Health Sciences

    Sugar Hill, Georgia

  • East West Medical Research Institute_Honolulu

    Honolulu, Hawaii

  • Elite Clinical Trials

    Blackfoot, Idaho

  • Cedar-Crosse Research Center

    Chicago, Illinois

  • Clinical Invest Special_Gurnee

    Gurnee, Illinois

  • Central Illinois Diabetes and Clinical Research

    Springfield, Illinois

Showing 40 of 198 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.